Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Adverse Events
Biotech
FDA questions benefit-risk profile of Geron's imetelstat
With 99% of patients having an adverse event, the FDA is skeptical that the benefit of Geron’s MDS medicine imetelstat outweighs the risks.
Annalee Armstrong
Mar 12, 2024 12:20pm
Rapt faces clinical hold after liver failure in immunology trial
Feb 20, 2024 10:42am
Inventiva pauses MASH study over patient's raised liver enzymes
Feb 16, 2024 8:15am
Stoke shares drop 30% as Dravet drug posts high adverse events
Jul 25, 2023 11:49am
AstraZeneca stock slides as pivotal ADC readout spooks investors
Jul 3, 2023 6:20am
Death triggers pause of 2seventy CAR-T cell therapy AML trial
Jun 14, 2023 8:30am